2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
OTHER
8
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
pembrolizumab
1029
Carboplatin
966
Paclitaxel
941
Gemcitabine
798
Cisplatin
754
Docetaxel
697
Bevacizumab
638
Nivolumab
519
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
468
Fluorouracil
424
Dexamethasone
409
Rituximab
391
Oxaliplatin
351
Injections
344
Trastuzumab
313
atezolizumab
311
Cetuximab
291
Leucovorin
288
Irinotecan
269
130-nm albumin-bound paclitaxel
255
Prednisone
250
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
215
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interleukins
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts